Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma

✍ Scribed by Paul Y. Holoye; David T. Carr; Hari M. Dhingra; Bonnie S. Glisson; Jin S. Lee; William K. Murphy; Theera Umsawasdi; Diane Jeffries

• Publisher: Springer US
• Year: 1988
• Tongue: English
• Weight: 115 KB
• Volume: 6
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/bf00175401

✦ Synopsis

Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.